Compounded tirzepatide typically costs between $349 and $699 per month, depending on the provider and your dose. That’s roughly a third to half the price of brand-name versions like Mounjaro and Zepbound, which list at about $1,080 to $1,086 for a 28-day supply.
Monthly Cost by Provider Tier
Most compounded tirzepatide is sold through telehealth platforms and specialty pharmacies using one of two pricing models: flat-rate or tiered by dose. Flat-rate pricing is more common, meaning you pay the same amount whether you’re on a starting dose or a higher maintenance dose.
Budget providers charge $349 to $399 per month, which adds up to roughly $4,200 to $4,800 per year. Mid-range providers fall between $450 and $549 per month, or $5,400 to $6,600 annually. Premium providers charge $550 to $699 per month, putting the annual cost between $6,600 and $8,400. In most cases, these prices include the consultation, medication, injection supplies, and shipping. Premium providers don’t necessarily offer a different product. The medication itself is often identical, just packaged with more marketing or added support services.
Some providers use tiered pricing instead, where costs rise as your dose increases. A typical tiered structure looks like this:
- 2.5 to 5 mg: $299 to $349 per month
- 7.5 to 10 mg: $399 to $499 per month
- 12.5 to 15 mg: $499 and up per month
If you’re just starting out and expect to stay on a lower dose for a while, tiered pricing can save you money in the early months. But if you anticipate titrating up, a flat-rate plan may cost less over time.
How Location Affects Price
Where you live can shift your monthly cost by $50 to $100. States like Texas, Florida, and Arizona tend to sit at the lower end, with prices between $349 and $450 per month. New York, California, and Illinois skew higher, typically ranging from $399 to $549 per month. Since most providers ship nationwide, you aren’t locked into your local market. Shopping across state lines through telehealth platforms is one of the simplest ways to find a lower price.
Compounded vs. Brand-Name Pricing
Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) lists at around $1,080 per month before insurance. If your insurance covers it, your copay could be significantly lower, but many plans exclude weight-loss medications entirely or impose prior authorization hurdles that delay access for weeks.
Compounded tirzepatide is almost always purchased out of pocket, which means the sticker price is the real price. At the low end ($349 per month), you’d spend about $4,200 a year. At the high end ($699), that climbs to roughly $8,400. Even the most expensive compounded option still costs less than a year of brand-name tirzepatide at list price, which runs close to $13,000 annually.
Using HSA or FSA Funds
Compounded tirzepatide is eligible for HSA and FSA reimbursement in most cases, as long as a licensed provider prescribes it for a diagnosed medical condition. That includes obesity, type 2 diabetes, overweight with related health problems, or obstructive sleep apnea. The IRS doesn’t distinguish between brand-name and compounded formulations. What matters is the prescription and the diagnosis behind it.
If the prescription is purely for cosmetic weight loss with no documented diagnosis, most FSA administrators will deny the claim. To avoid issues, keep three things on file: your prescription, an itemized receipt, and a letter of medical necessity from your provider tied to a specific diagnosis code.
What the Price Typically Includes
Most telehealth and online compounding providers bundle everything into one monthly fee: the medication itself, a provider consultation, syringes or injection supplies, and shipping. This is especially true of flat-rate plans. Before signing up with any provider, confirm what’s included. A few providers charge separately for initial consultations (often $50 to $100) or require you to purchase supplies on your own. Alcohol swabs and syringes are inexpensive if bought separately, usually a few dollars, but unexpected add-ons can be frustrating when you’re already comparing prices.
Why Compounded Versions Cost Less
Compounding pharmacies can produce tirzepatide at a fraction of the brand-name cost because they aren’t paying for the clinical trials, marketing, or regulatory overhead that Eli Lilly invested in Mounjaro and Zepbound. The raw ingredient cost to produce a single dose is remarkably low. The price you pay covers the pharmacy’s labor, quality testing, provider consultations, and business costs rather than pharmaceutical development.
There are two types of compounding pharmacies to be aware of. Section 503A pharmacies compound medications for individual patients based on specific prescriptions. Section 503B pharmacies, also called outsourcing facilities, can produce larger batches and are subject to more FDA oversight, including regular inspections. Both types are legal, but they follow different rules around how much they can produce and under what conditions.
The Shortage List and Legal Availability
Compounding pharmacies were initially allowed to make tirzepatide because the FDA placed the drug on its shortage list in December 2022. The FDA removed tirzepatide from the shortage list in October 2024 after determining that supply from Eli Lilly met or exceeded demand. This matters because once a drug is no longer in shortage, the legal basis for compounding near-copies of FDA-approved products narrows significantly.
Under current FDA guidance, 503A pharmacies can still fill a small number of individual prescriptions (four or fewer per month of a given compounded drug), and the FDA has said it does not intend to take enforcement action against compounders who stay within that limit. For 503B outsourcing facilities, the rules are stricter: they generally cannot produce compounded versions of commercially available drugs unless those drugs remain on the shortage list or the compounded version uses a bulk ingredient on a specific approved list.
This legal landscape is evolving. Some compounding pharmacies continue to sell tirzepatide, while others have paused or reformulated their offerings. Pricing and availability could shift as the FDA clarifies enforcement. If you’re currently using compounded tirzepatide, it’s worth checking periodically whether your pharmacy’s supply remains uninterrupted.
What to Watch for When Comparing Prices
Not all compounded tirzepatide is formulated the same way. Some pharmacies use the base form of tirzepatide, which is the same active ingredient found in Mounjaro and Zepbound. Others use salt forms (like tirzepatide sodium or acetate), which are cheaper to source but sit in a legal gray area. The FDA has raised questions about whether salt forms meet the requirements for legal compounding, since they aren’t the same active ingredient listed on FDA-approved product labels.
If a provider’s price seems dramatically lower than the $349 floor that most reputable pharmacies charge, it’s worth asking which form of tirzepatide they use. A very low price can sometimes reflect the use of a cheaper salt form rather than the base. Reports from users vary on whether salt forms feel different in practice, but the regulatory uncertainty alone is reason to ask the question before you buy.